Drug intelligence / Profile preview

tucotuzumab celmoleukin

Development stage: Phase 2
Lead developer: Merck KGaA
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Intravesical, Intraperitoneal

Overview

Tucotuzumab celmoleukin is a recombinant fusion protein composed of a humanized monoclonal antibody targeting the epithelial cell adhesion molecule (EpCAM) linked to an active interleukin-2 (IL2) molecule. It functions as an immunocytokine, delivering IL2 directly to EpCAM-expressing tumor cells, thereby stimulating immune responses against cancer. The drug was developed as an antineoplastic agent and has demonstrated immunologic activity in cancer patients. Its mechanism involves both antibody-dependent cell cytotoxicity and immunostimulation via IL2 receptor activation[1][3][4][6].

Other names: tucotuzumab celmoleukin

Targets

EPCAM (Epithelial cell adhesion molecule)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on tucotuzumab celmoleukin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tucotuzumab celmoleukin.

Explore the full profile